Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Anaplastic thyroid carcinoma exhibits intratumoral molecular homogeneity for a therapeutic target panel.

Deen S, Griffith OL, Masoudi H, Gown A, Jones SJ, Wiseman SM.

Anticancer Res. 2009 Jul;29(7):2437-44.

2.

Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma.

Wiseman SM, Griffith OL, Deen S, Rajput A, Masoudi H, Gilks B, Goldstein L, Gown A, Jones SJ.

Arch Surg. 2007 Aug;142(8):717-27; discussion 727-9.

PMID:
17709725
3.

Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis.

Wiseman SM, Melck A, Masoudi H, Ghaidi F, Goldstein L, Gown A, Jones SJ, Griffith OL.

Ann Surg Oncol. 2008 Oct;15(10):2811-26. doi: 10.1245/s10434-008-0034-8. Epub 2008 Jul 9.

PMID:
18612701
4.

Anaplastic thyroid cancer evolved from papillary carcinoma: demonstration of anaplastic transformation by means of the inter-simple sequence repeat polymerase chain reaction.

Wiseman SM, Loree TR, Hicks WL Jr, Rigual NR, Winston JS, Tan D, Anderson GR, Stoler DL.

Arch Otolaryngol Head Neck Surg. 2003 Jan;129(1):96-100.

PMID:
12525202
5.

FOXA1 is a potential oncogene in anaplastic thyroid carcinoma.

Nucera C, Eeckhoute J, Finn S, Carroll JS, Ligon AH, Priolo C, Fadda G, Toner M, Sheils O, Attard M, Pontecorvi A, Nose V, Loda M, Brown M.

Clin Cancer Res. 2009 Jun 1;15(11):3680-9. doi: 10.1158/1078-0432.CCR-08-3155. Epub 2009 May 26.

6.

ITCH is a putative target for a novel 20q11.22 amplification detected in anaplastic thyroid carcinoma cells by array-based comparative genomic hybridization.

Ishihara T, Tsuda H, Hotta A, Kozaki K, Yoshida A, Noh JY, Ito K, Imoto I, Inazawa J.

Cancer Sci. 2008 Oct;99(10):1940-9. doi: 10.1111/j.1349-7006.2008.00900.x.

7.

Encapsulated anaplastic thyroid carcinoma transformed from follicular carcinoma: a case report.

Rapkiewicz A, Roses D, Goldenberg A, Levine P, Bannan M, Simsir A.

Acta Cytol. 2009 May-Jun;53(3):332-6.

PMID:
19534279
8.

COX-2 expression in highly aggressive thyroid malignancies - indication for a possible therapeutic option?

Sheu SY, Grabellus F, Schwertheim S, Mann K, Ensinger C, Ofner D, Bockhorn M, Fuhrer D, Schmid KW.

Horm Metab Res. 2009 Apr;41(4):314-9. doi: 10.1055/s-0028-1102944. Epub 2008 Dec 1.

PMID:
19048457
9.

Changes in the balance between proliferation and apoptosis during the progression of malignancy in thyroid tumours.

Cvejic D, Selemetjev S, Savin S, Paunovic I, Tatic S.

Eur J Histochem. 2009 Apr-Jun;53(2):65-71. Erratum in: Eur J Histochem. 2009 Jul-Sep;53(3):188.

PMID:
19683979
10.

Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?

Tölle A, Jung M, Lein M, Johannsen M, Miller K, Moch H, Jung K, Kristiansen G.

BMC Cancer. 2009 Jul 21;9:248. doi: 10.1186/1471-2407-9-248.

11.

Overexpression of the angiogenic tetrapeptide AcSDKP in human malignant tumors.

Liu JM, Kusinski M, Ilic V, Bignon J, Hajem N, Komorowski J, Kuzdak K, Stepien H, Wdzieczak-Bakala J.

Anticancer Res. 2008 Sep-Oct;28(5A):2813-7.

12.
13.

S100A8 and S100A9 expression is a crucial factor for dedifferentiation in thyroid carcinoma.

Ito Y, Arai K, Nozawa R, Yoshida H, Hirokawa M, Fukushima M, Inoue H, Tomoda C, Kihara M, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Miyauchi A.

Anticancer Res. 2009 Oct;29(10):4157-61.

14.

Regulation of uptake of 18F-FDG by a follicular human thyroid cancer cell line with mutation-activated K-ras.

Prante O, Maschauer S, Fremont V, Reinfelder J, Stoehr R, Szkudlinski M, Weintraub B, Hartmann A, Kuwert T.

J Nucl Med. 2009 Aug;50(8):1364-70. doi: 10.2967/jnumed.109.062331.

15.

Expression of estrogen receptor, progesterone receptor, and vascular endothelial growth factor-A in thyroid cancer.

Kansakar E, Chang YJ, Mehrabi M, Mittal V.

Am Surg. 2009 Sep;75(9):785-9; discussion 789.

PMID:
19774949
16.

Altered chemokine receptor expression in papillary thyroid cancer.

González HE, Leiva A, Tobar H, Böhmwald K, Tapia G, Torres J, Mosso LM, Bueno SM, Gonzalez P, Kalergis AM, Riedel CA.

Thyroid. 2009 Sep;19(9):957-65. doi: 10.1089/thy.2008.0432.

PMID:
19731977
17.

Ultrasound features of suture granulomas in the thyroid bed after thyroidectomy for papillary thyroid carcinoma with an emphasis on their differentiation from locally recurrent thyroid carcinomas.

Kim JH, Lee JH, Shong YK, Hong SJ, Ko MS, Lee DH, Choi CG, Kim SJ.

Ultrasound Med Biol. 2009 Sep;35(9):1452-7. doi: 10.1016/j.ultrasmedbio.2009.04.009. Epub 2009 Jul 17.

PMID:
19616361
18.

Clinical implications of molecular markers in follicular cell-derived thyroid cancer.

Pinto AE, Leite V, Soares J.

Expert Rev Mol Diagn. 2009 Oct;9(7):679-94. doi: 10.1586/erm.09.54. Review.

PMID:
19817553
19.

Morphometric and immunohistochemical study of angiogenic marker expressions in invasive ductal carcinoma of human breast.

Safwat MD, Habib F, Elayat A, Oweiss N, Reffat S, Algaidi S.

Folia Morphol (Warsz). 2009 Aug;68(3):144-55.

PMID:
19722158
20.

Adding the p16(INK4a) marker to the traditional 3-marker (ER/Vim/CEA) panel engenders no supplemental benefit in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study.

Han CP, Lee MY, Kok LF, Ruan A, Wu TS, Cheng YW, Tyan YS, Lin CY.

Int J Gynecol Pathol. 2009 Sep;28(5):489-96. doi: 10.1097/PGP.0b013e31819e8ab4.

PMID:
19696622
Items per page

Supplemental Content

Write to the Help Desk